Normal hearing in a child with the m.1555AG mutation despite repeated exposure to aminoglycosides. Has the penetrance of this pharmacogenetic interaction been overestimated?
| Autor: | Sally J. Dawson, R. Suri, Tony Sirimanna, Ghada Al-Malky |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Pediatrics
medicine.medical_specialty Cystic Fibrosis Hearing loss DNA Mutational Analysis Penetrance Audiology Cystic fibrosis DNA Mitochondrial Ototoxicity Hearing otorhinolaryngologic diseases medicine Humans Point Mutation Child Hearing Loss Genetic testing medicine.diagnostic_test business.industry Hearing Tests Aminoglycoside General Medicine medicine.disease Aminoglycosides Otorhinolaryngology Pharmacogenetics RNA Ribosomal Child Preschool Pediatrics Perinatology and Child Health Mutation (genetic algorithm) Female medicine.symptom business |
| Zdroj: | International journal of pediatric otorhinolaryngology. 78(6) |
| ISSN: | 1872-8464 |
| Popis: | The mtDNA m.1555A>G mutation causes increased susceptibility to aminoglycoside ototoxicity resulting in significant hearing loss in 100% of reported exposed cases. Genetic and audiological assessments were conducted in a sample of 59 children with cystic fibrosis (CF) undergoing aminoglycoside treatment. Of the two m.1555G patients identified one had severe-profound deafness. Surprisingly, the second m.1555G patient exhibited well-preserved hearing despite repeated exposure. This may be a rare case of intact hearing in an m.1555G individual with aminoglycoside use. Alternatively, its penetrance may have been previously overestimated due to recruitment bias. Further studies are required to determine the true penetrance to inform m.1555A>G genetic testing in similar clinical scenarios. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect